Pipeline
Nabriva has a diversified drug portfolio of novel antibacterials, addressing unmet medical need in the hospital and community setting. The company’s portfolio comprises five programs, one thereof being a clinical phase I program and two being at late preclinical stage, expected to enter clinical trials within the next 6 months. All programs have been identified and developed internally, emphasizing Nabriva’s powerful development expertise and strong proprietary position.